Aribio Expands Partnership with Fujirebio for Development of In Vitro Diagnostics for Neurodegenerative Diseases

Aribio announced on August 12 that it will expand its strategic partnership with Fujirebio, a global leader in in vitro diagnostics. Through this collaboration, the companies aim to accelerate the development of early diagnosis and treatment monitoring technologies for neurodegenerative diseases such as Alzheimer's disease.

Fujirebio is a company with a 75-year history and more than 25 years of expertise in the diagnosis of neurodegenerative diseases. In May of this year, Fujirebio became the first in the world to receive approval from the U.S. Food and Drug Administration (FDA) for the Lumipulse-G, a test that measures the ratio of specific proteins (pTau217/β-Amyloid 1-42) in blood to enable early diagnosis of Alzheimer's disease. This innovative technology allows for highly accurate detection of Alzheimer's through blood samples, replacing the need for costly positron emission tomography (PET) scans or invasive cerebrospinal fluid (CSF) tests.

The development and approval of the Lumipulse-G diagnostic method critically relied on high-quality blood and CSF samples collected during the global Phase 3 clinical trial of Aribio's oral Alzheimer's treatment, AR1001. The AR1001 Phase 3 trial is currently underway, recruiting 1,535 early Alzheimer's patients across 230 clinical centers in 13 countries. These samples were obtained from early-stage Alzheimer's patients under strict standards and quality control procedures, not only meeting FDA approval criteria but also demonstrating global reliability.

Going forward, Aribio and Fujirebio plan to conduct strategic joint research to discover new biomarkers that can predict the progression of Alzheimer's disease and treatment response, as well as to clarify the correlation between the therapeutic effects of AR1001 and the suppression of disease progression.

Fred Kim, head of Aribio's U.S. branch, stated, "Aribio is focusing on the development of an oral Alzheimer's disease treatment, while also actively conducting research on blood biomarkers for diagnosis, evaluation of therapeutic effects, and follow-up monitoring. Through R&D collaboration with Fujirebio, we are building capabilities that go beyond new drug development to directly contribute to the commercialization of world-class diagnostic technologies."

Diana Dickson, Vice President of Diagnostics at Fujirebio, said, "High-quality, well-characterized patient samples are essential for the development and approval of in vitro diagnostics (IVD) for Alzheimer's disease and neurodegenerative disorders. By working closely with Aribio, we expect to further accelerate the development of new diagnostic technologies."

Meanwhile, Aribio is currently pursuing a merger with Kosdaq-listed company Solux, with the merger date set for November 4.

This content was produced with the assistance of AI translation services.